1. The aim of this study was to provide evidence that
anpirtoline, which is an agonist at 5-HT1B and 5-HT1D receptors and also displays submicromolar affinity for 5-HT1A recognition sites, in addition, acts as an antagonist at 5-HT3 receptors. 2. In radioligand binding studies on rat brain cortical membranes,
anpirtoline inhibited specific binding of [3H]-(S)-
zacopride to
5-HT3 receptor recognition sites (pKi: 7.53). 3. In N1E-115
neuroblastoma cells in which [14C]-
guanidinium was used as a tool to measure
cation influx through the
5-HT3 receptor channel, the 5-HT-induced influx was concentration-dependently inhibited by
anpirtoline. In this respect,
anpirtoline mimicked other
5-HT3 receptor antagonists; the rank order of potency was
ondansetron >
anpirtoline >
metoclopramide. 4. The concentration-response curve for
5-HT as a stimulator of [14C]-
guanidinium influx was shifted to the right by
anpirtoline (apparent pA2: 7.78). 5. In
urethane-anaesthetized rats,
anpirtoline inhibited (at lower potency than
zacopride and
tropisetron) the 5-HT- or
phenylbiguanide-induced
bradycardia (Bezold-Jarisch reflex), but did not induce this reflex by itself. 6.
Intravenous infusion of
cisplatin in the domestic pig caused a consistent
emetic response which was antagonized by
anpirtoline. 7. It is concluded that
anpirtoline, which was previously characterized as a
5-HT1 receptor agonist also proved to be a
5-HT3 receptor antagonist in several experimental models and, hence, exhibits a unique pattern of properties at different
5-HT receptors.